

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Sana Biotechnology, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or incorporation or organization)

**83-1381173**  
(IRS Employer Identification No.)

**188 East Blaine Street, Suite 400**  
**Seattle, Washington**  
(Address of Principal Executive Offices)

**98102**  
(Zip Code)

---

**Securities to be registered pursuant to Section 12(b) of the Act:**

**Title of each class  
to be so registered**  
Common stock, par value \$0.0001 per share

**Name of each exchange on which  
each class is to be registered**  
The Nasdaq Stock Market LLC

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-252061**.

Securities to be registered pursuant to Section 12(g) of the Act: **None**.

---

---

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

### Item 1. Description of Registrant's Securities to be Registered.

Sana Biotechnology, Inc. (the "**Company**") hereby incorporates by reference herein the description of its common stock, par value \$0.0001 per share (the "**Common Stock**"), to be registered hereunder, set forth under the heading "Description of Capital Stock" in the Company's prospectus constituting part of the Registration Statement on Form S-1 (File No. 333-252061) of the Company, initially filed on January 13, 2021 with the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended (the "**Securities Act**"). The description of the Common Stock included in any form of prospectus subsequently filed by the Company with the Commission shall be deemed to be incorporated by reference herein. The Common Stock is expected to be listed on The Nasdaq Stock Market LLC.

### Item 2. Exhibits.

Pursuant to the instructions as to exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: January 25, 2021

**Sana Biotechnology, Inc.**

By: /s/ Steven D. Harr, M.D.

Name: Steven D. Harr, M.D.

Title: President and Chief Executive Officer